XOMA Stock Analysis: Buy, Sell, or Hold?
XOMA - XOMA Royalty Corporation Common Stock
$25.66
0.69 (2.76%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 16, 2026
Get Alerted When XOMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XOMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: XOMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.21
Based on -19.2% avg growth
INTRINSIC VALUE TODAY
$3.24
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XOMA is currently trading at $25.66, which is considered oversold relative to its 30-day fair value range of $25.49 to $28.19. From a valuation perspective, the stock is trading at a discount (Forward PE: 38.1) compared to its historical average (43.9). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XOMA is in a strong downtrend. Immediate support is located at $24.14, while resistance sits at $29.46.
Market Sentiment: XOMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $64.50 (+151.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XOMA is in a strong downtrend. Immediate support is located at $24.14, while resistance sits at $29.46.
Market Sentiment: XOMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $64.50 (+151.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$25.49 -
$28.19
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding XOMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 151.4% below Wall St target ($64.50)
Fair Price Analysis
30-Day Fair Range
$25.49 -
$28.19
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$24.14
Resistance Level
$29.46
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
38.07
Wall Street Target
$64.50
(+151.4%)
Revenue Growth (YoY)
29.9%
Earnings Growth (YoY)
-47.8%
Profit Margin
45.9%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
38.1 vs 43.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$24.48
(-5%)
2-Year Target
$23.35
(-9%)
3-Year Target
$22.28
(-13%)
3-Yr Target (if PE normalizes)
(PE: 38→44)
$25.69
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 38.1, Growth: -42.4%)
$18.71
(+-27%)
Base:
(SPY PE: 22.3, Growth: -42.4%)
$10.96
(-57%)
Bear:
(PE: 19.0, Growth: -42.4%)
$9.31
(-64%)
📈
Valuation based on Current Earnings
Trailing PE: 32.88 | Current EPS (TTM): $0.75
Bull Case
$24.38
(-5%)
Analyst growth -10.1%, PE expands to 36.2
Base Case
$22.16
(-14%)
Market implied -10.1%, PE stable at 32.9
Bear Case
$16.77
(-35%)
Severe decline -20.0%, PE contracts to 28.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 38.1 to 43.9
Stabilization Target:
$29.59
(+15.3%)
PE Expansion Potential:
+15.3%
Last updated: January 31, 2026 11:19 PM ET
Data refreshes hourly during market hours. Next update: 12:19 AM
Data refreshes hourly during market hours. Next update: 12:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XOMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Thomas M Burns
SELL
4330 shares
2025-09-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 54 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$486 | 45 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$500 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$830 | 52 HOLD |
Advanced XOMA Option Strategies
Professional options setups generated by AI based on today's XOMA price and gamma walls.
